SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 8, 2003
ARQULE, INC.
(Exact Name of Issuer as Specified in Charter)
Delaware |
| 000-21429 |
| 04-3221586 |
(State or other jurisdiction |
| (Commission File Number) |
| (I.R.S. Employer |
19 Presidential Way
Woburn, MA
(Address of principal executive offices)
01801
(Zip code)
(781) 994-0300
(Registrant’s telephone number, including area code)
Item 5. Other Events and Regulation FD Disclosure
On July 17, 2003, ArQule, Inc. announced that it signed a definitive agreement to acquire Cyclis Pharmaceuticals, Inc. On September 8, 2003, ArQule, Inc. announced that it had completed the acquisition of Cyclis Pharmaceuticals, Inc. as contemplated by the previously-announced definitive agreement. The press release announcing completion of the acquisition is filed as Exhibit 99.1 hereto and incorporated herein by reference.
Item 7. Financial Statements and Exhibits
(c) Exhibits
99.1 Text of Press Release dated September 8, 2003.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ARQULE, INC. | |
| (Registrant) | |
| ||
| ||
| /s/ David C. Hastings |
|
| David C. Hastings | |
| Vice President and Chief Financial Officer | |
Date: September 16, 2003
2